New Investor for Immunservice GmbH

Immunservice completes a new financing round and gains the investor BPO Capital GmbH & Co. KG.

In Immunservice GmbH’s new financing round the current investors,  Prof. Dr. Michael Otto and the Hubertus Wald Stiftung, reinvested in the biotech company. Joining them now is BPO Capital GmbH & Co. KG – a venture capital holding founded by Benjamin Otto in order to support startup companies and   participate in new ideas. Prof. Dr. Edith Huland, founder and CEO of Immunservice GmbH, stressed: „We are delighted that with BPO Capital we were able to win the trust of another renowned investor. We will continue to focus on growth and expanding our portfolio with innovative products and are proud that our longstanding investors continue to be on board.”

Immunservice GmbH develops biological drugs that activate the body’s own immune system to eliminate cancerous and viral infections. Playing a key role in this immune defense is interleukin-2, an immune hormone that occurs naturally in the body and is essential for life. Immunservice produces interleukin-2 for drug development in an innovative form for special applications. Studies in patients have shown that interleukin-2 can cure serious diseases and it is therefore the basis for development of immunological drug products from Immunservice.  Immunservice focuses on kidney cancer and melanoma. Interleukin-2 has already been shown to be effective in and even to cure these diseases.  Immunservice specifically develops especially well tolerated therapies in order to preserve the patient’s quality of life during therapy and provide access to these innovative, potentially curative therapies.

Immunservice is GPH Magazine’s Cover Story in February 2017

We are very excited to appear as the cover story in the 01/2017 issue of GHP Magazine (Global Health Pharma). GHP Magazine specialises in three topics: the health of humans, animals and the environment. This is why Immunservice are even more be pleased to be featured in the magazine in an article presenting our work and our vision.

The online edition of the magazine including the final article can be found here. And read here the questionnaire we completed for the editors that was used to generate the article.

EXIST Transfer of Research Adds Prof. Edith Huland to Jury

The German Federal Ministry of Economic Affairs and Energy has appointed Prof. Edith Huland to the “Life Sciences” Expert Jury of the EXIST funding programme. Responsible for implementing the EXIST programme is the Research Centre Jülich (PTJ).EXIST Transfer of Research supports outstanding research-based start-up projects that involve expensive and high-risk development work. Open to all types of technology, the objective of this programme is to promote high-tech start-up projects requiring intense development work. More than 230 start-up projects have already been funded.The Expert Jury, all of whom already have their own start-up experience, make the funding recommendation. The “Life Sciences” Jury is made up of renowned representatives. Prof. Edith Huland looks forward to this new and exciting task.

VICTRESS Awards 2016 Nomination

VICTRESS Awards have been presented annually since 2005 to outstanding women who as impressive role models prove that success, leadership and femininity are compatible.

We are very pleased that Prof. Edith Huland – CEO of Immunservice GmbH – is one of the three finalists nominated for the VICTRESS SCIENCE Award 2016. Imagine a substance occurring naturally in our body – an immune hormone – that can cause immune cells to repel cancer, make it easier to overcome virus diseases, stop allergies, melt away excess pounds and much, much more. Edith Huland has been researching and developing this exciting field for years in Germany and abroad. Although she originally was not even supposed to receive her Abitur (academic high school diploma), she not only studied medicine but is a pediatrician, immunologist and cancer researcher. And when she was over 50 years old, she founded the Immunservice GmbH, where she works with a team of very ambitious women. She develops immune hormones based on biomimetic principles – in other words, inspired by nature – to formulate highly effective and well tolerated drug products. With “Pulmoleukin“ for the treatment of kidney cancer, whose marketing authorization is in preparation, she and her team are definitely on the right track. Edith Huland, the mother of two grown children, is married to the urologist Prof. Hartwig Huland and lives in Hamburg.

Our New Homepage Is Online!

We are happy to be able to present to you our new homepage. Our Internet presence in a new design is now more clearly structured and offers interested consumers, customers and partners comprehensive information about our company and products.

Featured is on our Online Shop, where you can easily order our products. We welcome praise and criticism.

Immunservice Finalizes Work to Establish a Webshop

Immunservice has just finalized work to establish a Webshop offering specialty products primarily for use in functional diagnostics (cell proliferation, bioassay, interleukin-2 activity, etc.). An important benefit is that all products are developed even in a stress test and optimized in a labour-intensive process for special applications.

Offered for cell culture of special cells are complete, ready-to-use media with long-term stability and formulated specifically for growth of interleukin-2 dependent cells. There is a special ready-to-use CTLL-2 medium in which these fastidious cells absolutely thrive. This proliferation can be visualized in colour and measured using WST modified specifically for CTLL-2 cells.

“We offer thoroughly tested specialty products that scientists otherwise have to mix and test themselves in a time-consuming process. This is unique and saves researchers time and leaves more room for their actual research. And those wanting to completely outsource function and proliferation tests will find top quality support at our company,” commented Immunservice.

Immunservice Successfully Develops Innovative Immunostimulant

Immunservice is currently very successfully developing an innovative immunostimulant for subsequent use in papillomavirus-induced tumours in humans and – through our partner company 4Animals Alsterscience – also in animals.

Following a very positive interim analysis of immunological toxicology studies, today a nationwide study in Germany began in horses with so-called “sarcoids”, locally aggressive tumours that are triggered by papillomaviruses and very difficult to treat.

“The results of  immunological studies in horses done so far are very promising, not just for animals but also for humans, where the virus can trigger cervical cancer and very difficult to treat tumours in mucous membranes,” said Prof. Huland, CEO of Immunservice.

Immunservice Has New Address

Our offices are now conveniently located close to our laboratories in the immediate vicinity of the University Hospital Eppendorf. We’re saying goodbye to Neue Wall and looking forward to the new rooms at Christoph-Probst-Weg 4, 20251 Hamburg.

The Future Holds New Possibilities for People Who Want to Lose Weight Effortlessly or Keep Resolutions to Stop Smoking.

Immunservice has developed an innovative immunotherapy for obesity and nicotine addiction and been granted a US patent for this discovery. The results of clinical studies by Immunservice scientists clearly indicate it is possible to make therapeutic use of the influence of immune hormones to make people want to eat light and healthy food and adopt a healthier lifestyle with no extra effort necessary. Moreover,   immune hormones apparently induce a natural lack of interest in nicotine consumption.

The discoveries by Immunservice GmbH offer new possibilities in the future to support people who want to lose weight or stick to resolutions to stop smoking. Patents have also been authorised in the European countries.

Dr. Michael Otto invests in innovative Immunotherapies to Cure and Prevent Cancer and Viral Infections

Immunservice GmbH has concluded a new round of financing (Series C) to secure development of the company’s biological immunotherapy methods for the long term. Joining the existing consortium of investors comprised of Helmut Piñata, the Hubertus-Wald-Sifting, the High-Tech-Gründerfonds (HTGF) and Hartwig Huland in the latest successful financing round was Dr. Michael Otto, entrepreneur and Chairman of the Board at the Otto Group.

Weiterlesen

Immunservice Welcomes Hubertus Wald Stiftung as New Investor

Hubertus Wald and his wife Renate are among the most generous and important patrons in Hamburg. For many years now the Hubertus Wald Stiftung, which they endowed, has promoted and financed important work in the areas of medical research, culture, and social projects primarily in Hamburg.

Through its investment in Immunservice GmbH, the Hubertus Wald Stiftung is combining two central foundation functions: the promotion of medical innovation and the long-term mission of increasing the foundation’s endowment.

Immunservice Pleased to Have New Investor Helmut Ponath Aboard

Helmut Ponath, CEO and Executive Spokesman for the Reederei NSB, is an experienced, extraordinarily successful Business Angel who is active in a variety of business fields with tremendous economic potential.